Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.54 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432672 | 1.00 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL13598665 | 1.00 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL733384 | 0.89 | PRMT5 (0.58) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL14089358 | 0.89 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL4430766 | 0.89 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL13598664 | 0.89 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL873612 | 0.89 | PRMT5 (0.58) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL13598817 | 0.89 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL733121 | 0.85 | ADORA3 (0.66) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL14782094 | 0.85 | ADORA3 (0.66) | ADORA3ADORA2AADORA1ADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |